Tracleer

Report
16 Pages
October 2018
Region: Global
Citeline
ID: 4775233

Drug Overview
Tracleer (bosentan; Johnson & Johnson) was the first oral therapy to be developed specifically for the treatment of PH. Tracleer is a competitive endothelin receptor type A and B antagonist, with over expression of endothelin in PH being associated with excessive vasoconstriction, pulmonary vasculature remodeling, and thrombosis formation.

Analyst Outlook
Once the market leader and the first-to-market drug for pulmonary hypertension (PH), Tracleer (bosentan; Johnson & Johnson), will now be succeeded by Johnson & Johnson’s next-generation endothelin receptor antagonist (ERA) Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku). Opsumit has demonstrated morbidity evidence that Tracleer lacks, and further possesses an improved hepatotoxicity profile. A combination of generic erosion and patients switching to Opsumit will set Tracleer’s sales into decline over the forecast period. Nevertheless, Tracleer will continue to benefit from prescribing trends increasingly integrating ERAs into combination regimens, which may help to offset losses.

OVERVIEW

Drug Overview
Product Profiles
Tracleer : Pulmonary hypertension

LIST OF FIGURES

Figure 1: Tracleer for pulmonary hypertension – SWOT analysis
Figure 2: The authors drug assessment summary of Tracleer for pulmonary hypertension
Figure 3: The authors drug assessment summary of Tracleer for pulmonary hypertension
Figure 4: Tracleer sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES

Table 1: Tracleer drug profile
Table 2: Tracleer pivotal trial data in pulmonary hypertension
Table 3: Tracleer sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9667EUR$10,000USD£8,309GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47369EUR$49,000USD£40,715GBP

Table of Contents

Related Topics

Related Reports

Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034

Endothelin Receptor Antagonist - Pipeline Insight, 2024

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

Pulmonary Arterial Hypertension Global Market Report 2024